Middle East Healthcare (Saudi German Health)
4009 · TASI — Main Market · 2026-07-29
Download report (PDF)
Snapshot Price 32.68 SAR
Market cap 3.01B SAR
P/E 10.67×
P/B 1.85×
ROE 17.34%
Dividend yield 0.00%
Revenue CAGR 15.47%
Valuation (Hajras) Fair value 27.55 SAR
Rating overvalued
Upside/(downside) -15.70%
DCF 81.04
DDM —
Graham 30.65
Discount rate 8.07%
DCF growth 8.00%
Financials SAR FY21 FY22 FY23 FY24 Revenue 1.87B 2.15B 2.65B 2.88B Net income 17.20M 75.18M 17.04M 282.00M EPS 0.19 0.82 0.19 3.06 DPS — — — — Equity 1.26B 1.33B 1.32B 1.63B
Analyst Price Targets Consensus (median) — SAR
Range — – — SAR
Aljazira Capital (hold) 30.00 SAR
This report is for informational purposes only and is not investment advice. Sources: Hajras valuation & financials, Yahoo/SEC EDGAR, and investment-house targets.